New antifungal drugs in ophthalmology

International Ophthalmology Clinics

Volumn 36, Issue 2, 1996, Pages 45-51

  O'Day, Denis M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; BUTOCONAZOLE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NATAMYCIN; OXICONAZOLE; POLYENE ANTIBIOTIC AGENT; PYRROLE; SAPERCONAZOLE; TERCONAZOLE; TIOCONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; EYE INFECTION; FUSARIUM; HISTOPLASMA CAPSULATUM; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MUCORALES; PRIORITY JOURNAL; REVIEW; SUBCONJUNCTIVAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

EID: 0029853679     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199603620-00006     Document Type: Review

References (27)

1. Gates C, Pinney RJ. Amphotericin B and its delivery by liposomal and lipid formulations. J Clin Pharm Ther 1993;18:147-253
2. Ayestarán A, López RM, Montoro JB, et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother 1996;40:609-612
3. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(suppl 1):S161-S169
4. Sugar AM. Fluconazole and itraconazole: current status and prospects for antifungal therapy. Curr Clin Top Infect Dis 1993;13:74-98
5. Vanden Bossche H. Itraconazole: a selective inhibitor of cytochrome p-450 dependent ergosterol biosynthesis. In: Fromtling RA, ed. Recent trends in the discovery, development, and evaluation of antifungal agents. Philadelphia: Prous Science, 1987:207-221
6. Sugar AM. Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination. Antimicrob Agents Chemother 1991;35:1669-1671
7. Albert MM, Graybill JR, Rinaldi MG. Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination. Antimicrob Agents Chemother 1991;35:1721-1725
8. Debruyne D, Ryckelynck J-P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24(1):10-27
9. O'Day DM. Orally administered antifungal therapy for experimental keratomycosis. Trans Am Ophthalmol Soc 1990;88:685-725
10. O'Day DM, Foulds G, Williams TE, et al. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol 1990;108:1006-1008
11. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987;31:6-10
12. Akler ME, Vellend H, McNeely DM, et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995;20:657-664
13. Borne MJ, Elliott JH, O'Day DM. Ocular fluconazole treatment of Candida parapsilosis endophthalmitis after failed intravitreal amphotericin B. Arch Ophthalmol 1993;111(10):1326-1327
14. Park SS, D'Amico DJ, Paton B, Baker AS. Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole. Antimicrob Agents Chemother 1995;39(4):958-963
15. Laatikainen L, Tuominen M, von Dickhoff K. Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol 1992;113:205-207
16. Filler SG, Crislip MA, Mayer CL, Edwards JE. Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother 1991;24:288-292
17. Del Palacio A, Cuétara MS, Ferro M, et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 1993;36:193-199
18. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851
19. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993;118:495-503
20. Schulman JA, Peyman G, Fiscella R, et al. Toxicity of intravitreal injection of fluconazole in the rabbit. Can J Ophthalmol 1987;22:304-306
21. Klippenstein K, O'Day DM, Robinson RD, et al. The qualitative evaluation of the pharmacokinetics of subconjunctivally injected antifungal agents in rabbits. Cornea 1993;12(6):512-516
22. O'Day DM, Ray WA, Robinson RD, Head WS. Differences in response in vivo to amphotericin B among Candida albicans strains. Invest Ophthalmol Vis Sci 1991;32(5):1569-1572
23. Vives T, Yee RW, Jalcedo K, et al. Topical 0.2% fluconazole in rabbit fungal-induced keratitis. Invest Ophthalmol Vis Sci 1992;33(suppl 4):776
24. Head WS, O'Day DM, Robinson RD, Tang R. Lack of efficacy of topically applied fluconazole or itraconazole on experimental Candida albicans keratitis in rabbits. Invest Ophthalmol Vis Sci 1994;35(suppl 4):1676
25. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987;9:S15-32
26. Jennings TS, Hardin TC. Treatment of aspergillosis with itraconazole. Ann Pharmacother 1993;27:1206-1211
27. O'Day DM, Head WS, Robinson RD, Yang R. Efficacy of subconjunctival itraconazole in the treatment of experimental Aspergillus keratomycosis. Curr Eye Res 1996 (in press)